Merck Agrees With ADAP Crisis Task Force To Help State AIDS Drug Assistance Programs Provide Access To Once-Daily HIV Treatment, IDVYNSO

Agreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligible individuals Merck (NYSE: MRK ), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to the company’s new once-daily HIV treatment, IDVYNSO™ (doravirine/islatravir).

In 2024, state ADAPs supported more than 250,000 people with HIV in the United States.

IDVYNSO was approved by the U.S.

Food and Drug Administration (FDA) in April 2026 as a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.